1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets

This BCC Research report provides an in-depth study of the liquid biopsy diagnostics industry. The global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region. The market sizes are given for the years 2014, 2015 and 2020.

Use this report to:
Analyze the market for liquid biopsy diagnostics in depth.
Gain information on liquid biopsy technologies, clinical applications, industry structure, important liquid biopsy funding initiatives, global markets, patent status and companies.
Learn about some of the top research initiatives that are contributing to liquid biopsy development.
Gain information on various liquid biopsy diagnostics markets, including for reproductive health, cancer and transplant diagnostics

Highlights

The global liquid biopsy market should reach nearly $4.5 billion in 2020 from $1.6 billion in 2015, registering a CAGR of 22.3% for the period of 2015-2020.
The cancer application market will increase at a CAGR of 36.2% over the forecast period to grow from $414.5 million in 2015 to $1.9 billion in 2020.
The non-cancer application market as a segment reached $1.2 billion in 2015 and should reach $2.5 billion by 2020 increasing at a CAGR of 15.7%.


STUDY GOALS AND OBJECTIVES

This BCC Research report provides an in-depth study of the liquid biopsy diagnostics industry, an emerging industry with high market potential. The global market is analyzed by application, biomarker type, analysis platform, analysis purpose and geographic region. The market sizes are given for the years 2014, 2015 and 2020.
Market segments that provide exceptional growth opportunities include cancer monitoring and organ transplant surveillance.

The report provides a comprehensive discussion of liquid biopsy technologies, clinical applications, industry structure, important liquid biopsy funding initiatives, global markets, patent status and companies. The report is designed to aid companies in their strategic planning efforts relating to life science tools and diagnostics

REASONS FOR DOING THE STUDY

Traditional biopsy methods are often invasive and uncomfortable, and carry risks of side effects. Liquid biopsy addresses these issues because it is noninvasive and carries little, if any, side effect risks.

With the advent of the age of genomics and personalized medicine, it is critical for clinicians to have diagnostic tools that can be used on a regular basis to monitor, conduct surveillance, guide treatment or otherwise give valuable genomic information about a disease. Liquid biopsy provides this capability, and thus is of high interest to the medical community.

Liquid biopsy enabling technologies are rapidly making progress, and this is adding to the market growth momentum. Downstream analysis technologies like next-generation sequencing (NGS) and digital polymerase chain reaction (PCR) are progressing in capabilities, efficiency and costs. Upstream technologies like icrofluidics, cell capture and DNA amplification are also making significant progress.

Based on these trends, liquid biopsy markets are rapidly emerging, and the need for industry and market characterization is great.

Also, liquid biopsy is extending its market penetration into high-volume diagnostics segments, including average risk noninvasive prenatal testing (NIPT) and cancer monitoring.

The outstanding growth potential for liquid biopsy diagnostics makes it particularly timely for doing this report.

Table Of Contents

Liquid Biopsy Research Tools, Services and Diagnostics: Global Markets
CHAPTER 1 INTRODUCTION 2
STUDY GOALS AND OBJECTIVES 2
REASONS FOR DOING THE STUDY 2
CONTRIBUTION OF THE STUDY AND FOR WHOM 3
SCOPE AND FORMAT 3
METHODOLOGY 4
INFORMATION SOURCES 4
ANALYST'S CREDENTIALS 4
RELATED BCC RESEARCH REPORTS 4
BCC RESEARCH WEBSITE 5
DISCLAIMER 5
CHAPTER 2 EXECUTIVE SUMMARY 7
SUMMARY TABLE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, THROUGH
2020 ($ MILLIONS) 7
SUMMARY FIGURE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, 2014-2020 ($
MILLIONS) 8
CHAPTER 3 OVERVIEW 11
INTRODUCTION 11
TABLE 1 LIQUID BIOPSY SAMPLE TYPES 11
REPORT SCOPE 12
TABLE 2 LIQUID BIOPSY REPORT SCOPE 12
LIQUID BIOPSY VERSUS TRADITIONAL BIOPSY 12
MARKETS 13
TABLE 3 LIQUID BIOPSY MARKET BY ANALYSIS TYPE, THROUGH 2020 ($ MILLIONS) 13
GROWTH DRIVING FORCES 14
TABLE 4 GROWTH DRIVING FORCES 14
KEY TRENDS 15
TABLE 5 KEY TRENDS IN LIQUID BIOPSY 15
INDUSTRY 16
TABLE 6 SINGLE CELL ANALYSIS INDUSTRY SUBSECTORS 16
CHAPTER 4 TECHNOLOGIES 18
LIQUID BIOPSY BIOMARKERS 18
TABLE 7 LIQUID BIOPSY BIOMARKER CLASSES 18
CANCER GENOMICS 19
FIGURE 1 HOW CANCER GENOMICS DRIVES LIQUID BIOPSY 19
TABLE 8 SINGLE CELL ANALYSIS TO IDENTIFY CANCER DRIVER MUTATIONS 20
TABLE 9 GENOMICS-BASED ONCOLOGY WORKFLOW 21
NONINVASIVE PRENATAL TESTING 22
TABLE 10 CELL-FREE DNA ANALYSIS APPROACHES 23
CIRCULATING TUMOR CELL (CTC) TECHNOLOGIES 24
TABLE 11 UNIQUE TECHNICAL CHALLENGES OF CTC CAPTURE AND ANALYSIS 24
CTC WORKFLOW 25
TABLE 12 CTC WORKFLOW 25
CELL ISOLATION TECHNOLOGIES 26
TABLE 13 CELL DIFFERENTIATORS 26
TABLE 14 CELL ISOLATION TECHNOLOGIES 27
CTC SAMPLE PREPARATION TECHNOLOGIES 28
TABLE 15 CTC SAMPLE PREPARATION TECHNOLOGIES 29
CTC DOWNSTREAM ANALYSIS TECHNOLOGIES 29
TABLE 16 SINGLE CELL ANALYSIS TECHNOLOGIES 30
COMPARISON OF LIQUID BIOPSY WITH CONVENTIONAL BIOPSY 30
CANCER TESTING 31
TABLE 17 ESTIMATED ANNUAL BIOPSY PROCEDURES PERFORMED IN THE U.S. FOR
SELECTED CANCERS 31
TABLE 18 MAIN RISKS FOR NEEDLE-BASED TISSUE BIOPSIES 31
TABLE 19 FACTORS IN TISSUE BIOPSY 33
PRENATAL TESTING 33
TABLE 20 INVASIVE PRENATAL TESTING TECHNOLOGIES 34
TABLE 21 INVASIVE VERSUS NONINVASIVE PRENATAL TECHNOLOGIES 35
CHAPTER 5 LIQUID BIOPSY INITIATIVES 37
KEY COLLABORATIVE INITIATIVES 37
TABLE 22 KEY LIQUID BIOPSY RESEARCH AND DEVELOPMENT PROGRAMS 37
CAMBRIDGE SINGLE CELL ANALYSIS CORE FACILITY 37
CANCER-ID 38
CTC TRAP CONSORTIUM 38
EARLY CANCER DETECTION CONSORTIUM 38
HEMATOLOGIC ONCOLOGY CONSORTIUM 38
NATIONAL CENTER FOR SINGLE CELL BIOLOGY 39
PRECISION MEDICINE INITIATIVE 39
SINGLE CELL ANALYSIS PROGRAM 39
WORLDWIDE INNOVATIVE NETWORKING (WIN) CONSORTIUM 40
CHAPTER 6 LIQUID BIOPSY APPLICATIONS 42
INTRODUCTION 42
TABLE 23 SOURCE OF FOREIGN BIOMARKERS FOR LIQUID BIOPSY APPLICATIONS 42
CANCER APPLICATIONS 42
PRECISION MEDICINE 42
TABLE 24 PERSONALIZED MEDICINE DRIVEN BY CANCER COMMON GENETIC
MUTATIONS 42
CANCER BIOMARKER STATUS 43
TABLE 25 CANCER LIQUID BIOPSY BIOMARKER CLINICAL STATUS 44
CANCER MARKET SEGMENTS 45
TABLE 26 CANCER LIQUID BIOPSY MARKET SEGMENTS 45
REPRODUCTIVE HEALTH APPLICATIONS 47
TABLE 27 NIPT AS A SCREENING APPLICATION 47
TABLE 28 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN
SCREENING 48
TRANSPLANT DIAGNOSTICS APPLICATIONS 49
TABLE 29 TRANSPLANT DIAGNOSTICS APPLICATIONS 49
CHAPTER 7 LIQUID BIOPSY INDUSTRY 51
INTRODUCTION 51
TABLE 30 KEY SEGMENTS WITHIN THE LIQUID BIOPSY INDUSTRY 51
NGS INSTRUMENT INDUSTRY 52
TABLE 31 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY 52
DROPLET DIGITAL PCR (DDPCR) INDUSTRY 55
TABLE 32 ADVANTAGES OF DDPCR FOR SINGLE CELL ANALYSIS 55
TABLE 33 DDPCR INDUSTRY 56
TARGET ENRICHMENT AND AMPLIFICATION INDUSTRY 56
TABLE 34 SINGLE CELL TARGET ENRICHMENT INDUSTRY 57
SINGLE CELL DNA POLYMERASE INDUSTRY 58
TABLE 35 SINGLE CELL DNA POLYMERASE INDUSTRY 58
NONINVASIVE PRENATAL TESTING INDUSTRY 59
TABLE 36 NGS NIPT INDUSTRY 60
TABLE 37 GLOBAL NIPT MARKET BY REGION AND COMPANY BY NUMBER OF TESTS,
2015 64
TABLE 38 GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC
COMPANIES, 2015 65
LIQUID BIOPSY INDUSTRY 67
TABLE 39 LIQUID BIOPSY INDUSTRY COMPANY FOCUS 68
CHAPTER 8 ACQUISITIONS AND STRATEGIC ALLIANCES 77
ACQUISITIONS 77
TABLE 40 LIQUID BIOPSY INDUSTRY ACQUISITIONS, JANUARY 2013-OCTOBER 2015 77
STRATEGIC ALLIANCES 80
TABLE 41 SINGLE CELL INDUSTRY STRATEGIC ALLIANCES, JANUARY
2013-OCTOBER 2015 80
CHAPTER 9 MARKETS 90
GROWTH DRIVING FORCES 90
TABLE 42 LIQUID BIOPSY MARKET GROWTH DRIVING FORCES 90
LIQUID BIOPSY MARKET 91
BY INDICATION 91
TABLE 43 LIQUID BIOPSY MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 91
BY BIOMARKER TYPE 92
TABLE 44 LIQUID BIOPSY MARKET BY BIOMARKER TYPE, THROUGH 2020 ($
MILLIONS) 92
BY ANALYSIS PLATFORM 92
TABLE 45 LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM, THROUGH 2020 ($
MILLIONS) 93
BY ANALYSIS PURPOSE 93
TABLE 46 LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($
MILLIONS) 93
NONINVASIVE PRENATAL TESTING MARKET 94
TABLE 47 NIPT MARKET BY RISK TYPE, THROUGH 2020 ($ MILLIONS) 95
TABLE 48 NIPT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS) 96
TABLE 49 NIPT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS) 98
TABLE 50 NIPT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS) 99
TABLE 51 NGS NIPT MARKET BY INSTRUMENT TYPE, THROUGH 2020 ($ MILLIONS) 100
CANCER MARKET 100
TABLE 52 CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 100
TABLE 53 CANCER MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS) 102
TABLE 54 EARLY CANCER DETECTION (MM/NO.) 103
TABLE 55 CANCER MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS) 105
TABLE 56 CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS) 106
CTC CANCER MARKET 107
TABLE 57 CTC CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 107
TABLE 58 CTC CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($
MILLIONS) 109
CFDNA CANCER MARKET 110
TABLE 59 CFDNA CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 110
TABLE 60 CFDNA CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($
MILLIONS) 112
EV CANCER MARKET 113
TABLE 61 EV CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 113
TABLE 62 EV CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($
MILLIONS) 114
TRANSPLANT MARKET 115
TABLE 63 TRANSPLANT MARKET BY ORGAN TYPE, THROUGH ($ MILLIONS) 115
TABLE 64 U.S. LIQUID BIOPSY TRANSPLANT MARKET (PROCEDURES PER
YEAR/NUMBER OF PATIENTS) 116
TABLE 65 TRANSPLANT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($
MILLIONS) 117
TABLE 66 TRANSPLANT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($
MILLIONS) 117
TABLE 67 TRANSPLANT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($
MILLIONS) 118
LIQUID BIOPSY MARKET BY REGION 119
TABLE 68 LIQUID BIOPSY MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 119
TABLE 69 CANCER MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 120
TABLE 70 NIPT MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 120
TABLE 71 TRANSPLANT MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 122
CHAPTER 10 PATENTS 125
CIRCULATING TUMOR CELL PATENTS 125
TABLE 72 CTC PATENTS, 2005-2015 125
CELL-FREE DNA PATENTS 126
TABLE 73 CELL-FREE DNA PATENTS, 2005-2015 126
CHAPTER 11 COMPANY PROFILES 128
AFFYMETRIX 128
AGILENT TECHNOLOGIES INC. 128
ANGLE PLC 130
ANNOROAD GENE TECHNOLOGY 131
APOCELL 132
ASURAGEN INC. 132
AVIVA BIOSCIENCES 133
BECTON, DICKINSON AND CO. 134
BERRY GENOMICS CO. LTD. 135
BGI SHENZHEN 136
BIOCARTIS NV 137
BIOCEPT INC. 138
BIOFLUIDICA INC. 139
BIO-RAD LABORATORIES INC. 140
BOREAL GENOMICS 140
CELL MICROSYSTEMS INC. 141
CELLSEE DIAGNOSTICS INC. 141
CELLULAR RESEARCH INC. 142
CHRONIX BIOMEDICAL 143
CIRCULOGENE THERANOSTICS 143
CIRCULOMICS INC. 144
CLONTECH LABORATORIES INC. 144
CYNVENIO BIOSYSTEMS INC. 144
CYTOTRACK APS 145
DANAHER CORP. 145
DIAGNOLOGIX LLC 146
DNA ELECTRONICS LTD. 147
EPIC SCIENCES 148
EXOSOME DIAGNOSTICS INC. 148
FLUIDIGM CORP. 149
FOUNDATION MEDICINE 150
FLUXION BIOSCIENCES INC. 151
GATC BIOTECH AG 151
GE HEALTHCARE 152
GENOMIC HEALTH INC. 153
GIGAGEN INC. 154
GOOD START GENETICS INC. 154
GUARDANT HEALTH INC. 155
HTG MOLECULAR DIAGNOSTICS INC. 156
ILLUMINA INC. 157
TABLE 74 NEW PLATFORMS INTRODUCED BY ILLUMINA, 2015 157
JOHNSON and JOHNSON 161
KELLBENX INC. 162
LABORATORY CORP. OF AMERICA INC. 163
MDX HEALTH INC. 164
MERCK KGAA 165
MYRIAD GENETICS INC. 165
NATERA INC. 167
NEOGENOMICS INC. 168
NEW ENGLAND BIOLABS 169
NEW ONCOLOGY AG 169
NUGEN TECHNOLOGIES INC. 170
OXFORD GENE TECHNOLOGY 171
OXFORD NANOPORE TECHNOLOGIES LTD. 171
PACIFIC BIOSCIENCES OF CALIFORNIA INC. 172
PATHWAY GENOMICS CORP. 174
PERSONAL GENOME DIAGNOSTICS INC. 175
PROVISTA DIAGNOSTICS INC. 176
QIAGEN NV 176
RAINDANCE TECHNOLOGIES INC. 178
RARECELLS SAS 179
RARECYTE INC. 179
RESOLUTION BIOSCIENCE INC. 179
ROCHE HOLDING AG 180
TABLE 75 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING 181
RUBICON GENOMICS 183
SALVEO DX 183
SCREENCELL 183
SENGENICS INTERNATIONAL PTE LTD. 184
SEQUENOM INC. 184
SILICON BIOSYSTEMS 186
SPHERE FLUIDICS LTD. 186
STRAND LIFE SCIENCES 187
STRATEC BIOMEDICAL AG 187
SYGNIS AG 187
SYSMEX INOSTICS 188
TAI DIAGNOSTICS INC. 188
THERMO FISHER SCIENTIFIC INC. 188
THORNE DIAGNOSTICS INC. 190
TROVAGENE INC. 190
TRANSGENOMIC INC. 191
VITATEX INC. 191
WAFERGEN BIO-SYSTEMS INC. 192
TABLE 76 WAFERGEN STRATEGIC ALLIANCES 192
XCELL BIOSCIENCES INC. 193
YIKON GENOMICS CO. LTD. 193
ZEPHYRUS BIOSCIENCES INC. 194


LIST OF TABLES

SUMMARY TABLE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, THROUGH 2020
($ MILLIONS) 7
TABLE 1 LIQUID BIOPSY SAMPLE TYPES 11
TABLE 2 LIQUID BIOPSY REPORT SCOPE 12
TABLE 3 LIQUID BIOPSY MARKET BY ANALYSIS TYPE, THROUGH 2020 ($ MILLIONS) 13
TABLE 4 GROWTH DRIVING FORCES 14
TABLE 5 KEY TRENDS IN LIQUID BIOPSY 15
TABLE 6 SINGLE CELL ANALYSIS INDUSTRY SUBSECTORS 16
TABLE 7 LIQUID BIOPSY BIOMARKER CLASSES 18
TABLE 8 SINGLE CELL ANALYSIS TO IDENTIFY CANCER DRIVER MUTATIONS 20
TABLE 9 GENOMICS-BASED ONCOLOGY WORKFLOW 21
TABLE 10 CELL-FREE DNA ANALYSIS APPROACHES 23
TABLE 11 UNIQUE TECHNICAL CHALLENGES OF CTC CAPTURE AND ANALYSIS 24
TABLE 12 CTC WORKFLOW 25
TABLE 13 CELL DIFFERENTIATORS 26
TABLE 14 CELL ISOLATION TECHNOLOGIES 27
TABLE 15 CTC SAMPLE PREPARATION TECHNOLOGIES 29
TABLE 16 SINGLE CELL ANALYSIS TECHNOLOGIES 30
TABLE 17 ESTIMATED ANNUAL BIOPSY PROCEDURES PERFORMED IN THE U.S. FOR
SELECTED CANCERS 31
TABLE 18 MAIN RISKS FOR NEEDLE-BASED TISSUE BIOPSIES 31
TABLE 19 FACTORS IN TISSUE BIOPSY 33
TABLE 20 INVASIVE PRENATAL TESTING TECHNOLOGIES 34
TABLE 21 INVASIVE VERSUS NONINVASIVE PRENATAL TECHNOLOGIES 35
TABLE 22 KEY LIQUID BIOPSY RESEARCH AND DEVELOPMENT PROGRAMS 37
TABLE 23 SOURCE OF FOREIGN BIOMARKERS FOR LIQUID BIOPSY APPLICATIONS 42
TABLE 24 PERSONALIZED MEDICINE DRIVEN BY CANCER COMMON GENETIC
MUTATIONS 42
TABLE 25 CANCER LIQUID BIOPSY BIOMARKER CLINICAL STATUS 44
TABLE 26 CANCER LIQUID BIOPSY MARKET SEGMENTS 45
TABLE 27 NIPT AS A SCREENING APPLICATION 47
TABLE 28 ETHICAL ISSUES ASSOCIATED WITH PRENATAL AND NEWBORN
SCREENING 48
TABLE 29 TRANSPLANT DIAGNOSTICS APPLICATIONS 49
TABLE 30 KEY SEGMENTS WITHIN THE LIQUID BIOPSY INDUSTRY 51
TABLE 31 NEXT-GENERATION SEQUENCING INSTRUMENT COMPANIES SUMMARY 52
TABLE 32 ADVANTAGES OF DDPCR FOR SINGLE CELL ANALYSIS 55
TABLE 33 DDPCR INDUSTRY 56
TABLE 34 SINGLE CELL TARGET ENRICHMENT INDUSTRY 57
TABLE 35 SINGLE CELL DNA POLYMERASE INDUSTRY 58
TABLE 36 NGS NIPT INDUSTRY 60
TABLE 37 GLOBAL NIPT MARKET BY REGION AND COMPANY BY NUMBER OF TESTS,
2015 64
TABLE 38 GERMANY NGS-BASED NONINVASIVE PRENATAL DIAGNOSTIC COMPANIES,
2015 65
TABLE 39 LIQUID BIOPSY INDUSTRY COMPANY FOCUS 68
TABLE 40 LIQUID BIOPSY INDUSTRY ACQUISITIONS, JANUARY 2013-OCTOBER 2015 77
TABLE 41 SINGLE CELL INDUSTRY STRATEGIC ALLIANCES, JANUARY 2013-OCTOBER
2015 80
TABLE 42 LIQUID BIOPSY MARKET GROWTH DRIVING FORCES 90
TABLE 43 LIQUID BIOPSY MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 91
TABLE 44 LIQUID BIOPSY MARKET BY BIOMARKER TYPE, THROUGH 2020 ($
MILLIONS) 92
TABLE 45 LIQUID BIOPSY MARKET BY ANALYSIS PLATFORM, THROUGH 2020 ($
MILLIONS) 93
TABLE 46 LIQUID BIOPSY MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($
MILLIONS) 93
TABLE 47 NIPT MARKET BY RISK TYPE, THROUGH 2020 ($ MILLIONS) 95
TABLE 48 NIPT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS) 96
TABLE 49 NIPT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS) 98
TABLE 50 NIPT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS) 99
TABLE 51 NGS NIPT MARKET BY INSTRUMENT TYPE, THROUGH 2020 ($ MILLIONS) 100
TABLE 52 CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 100
TABLE 53 CANCER MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($ MILLIONS) 102
TABLE 54 EARLY CANCER DETECTION (MM/NO.) 103
TABLE 55 CANCER MARKET BY BIOMARKER CLASS, THROUGH 2020 ($ MILLIONS) 105
TABLE 56 CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS) 106
TABLE 57 CTC CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 107
TABLE 58 CTC CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($
MILLIONS) 109
TABLE 59 CFDNA CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 110
TABLE 60 CFDNA CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($
MILLIONS) 112
TABLE 61 EV CANCER MARKET BY INDICATION, THROUGH 2020 ($ MILLIONS) 113
TABLE 62 EV CANCER MARKET BY ANALYSIS METHOD, THROUGH 2020 ($ MILLIONS) 114
TABLE 63 TRANSPLANT MARKET BY ORGAN TYPE, THROUGH ($ MILLIONS) 115
TABLE 64 U.S. LIQUID BIOPSY TRANSPLANT MARKET (PROCEDURES PER
YEAR/NUMBER OF PATIENTS) 116
TABLE 65 TRANSPLANT MARKET BY ANALYSIS PURPOSE, THROUGH 2020 ($
MILLIONS) 117
TABLE 66 TRANSPLANT MARKET BY BIOMARKER CLASS, THROUGH 2020 ($
MILLIONS) 117
TABLE 67 TRANSPLANT MARKET BY ANALYSIS METHOD, THROUGH 2020 ($
MILLIONS) 118
TABLE 68 LIQUID BIOPSY MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 119
TABLE 69 CANCER MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 120
TABLE 70 NIPT MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 120
TABLE 71 TRANSPLANT MARKET BY REGION, THROUGH 2020 ($ MILLIONS) 122
TABLE 72 CTC PATENTS, 2005-2015 125
TABLE 73 CELL-FREE DNA PATENTS, 2005-2015 126
TABLE 74 NEW PLATFORMS INTRODUCED BY ILLUMINA, 2015 157
TABLE 75 COMMERCIAL SEQUENCER COMPETITIVE POSITIONING 181
TABLE 76 WAFERGEN STRATEGIC ALLIANCES 192

LIST OF FIGURES

SUMMARY FIGURE GLOBAL LIQUID BIOPSY MARKET BY APPLICATION, 2014-2020 ($
MILLIONS) 8
FIGURE 1 HOW CANCER GENOMICS DRIVES LIQUID BIOPSY 19

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

Liquid Biopsy Market: Global Industry Analysis and Opportunity Assessment 2016-2026

  • $ 5000
  • Industry report
  • August 2016
  • by Future Market Insight Global & Consulting Pvt Ltd

Report Synopsis This report by Future Market Insights (FMI) examines the ‘Liquid Biopsy Market’ for the period 2016–2026. The primary objective of the report is to offer updates and information ...

Breast Biopsy Device Market Analysis By Test Type, By Product, By Guidance Type, By Region And Segment Forecasts To 2024

Breast Biopsy Device Market Analysis By Test Type, By Product, By Guidance Type, By Region And Segment Forecasts To 2024

  • $ 4950
  • Industry report
  • August 2016
  • by Grand View Research

The breast biopsy device market is expected to reach USD 911.2 million by 2024, according to a new report by Grand View Research, Inc. The Breast biopsy device market is projected to grow at a productive ...

Liquid Biopsy Market Size & Forecast By Application, By Sample Type, By Biomarker Type, By Technology and Trend Analysis from 2013 to 2030

Liquid Biopsy Market Size & Forecast By Application, By Sample Type, By Biomarker Type, By Technology and Trend Analysis from 2013 to 2030

  • $ 4950
  • Industry report
  • September 2016
  • by Grand View Research

Global liquid biopsies market is anticipated to reach 5,958.3 million by 2030, according to a new report by Grand View Research, Inc. As these less invasive biopsies are able to address a number of significant ...


Download Unlimited Documents from Trusted Public Sources

Biopsy Industry in the US

  • October 2016
    7 pages
  • Biopsy  

    Magnetic Resona...  

    Cancer  

  • United States  

View report >

Biopsy Industry in the US

  • August 2016
    2 pages
  • Biopsy  

  • United States  

    North America  

View report >

Biopsy Industry in the US

  • August 2016
    4 pages
  • Biopsy  

  • United States  

View report >

Related Market Segments :

Biopsy

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.